Followers | 10 |
Posts | 343 |
Boards Moderated | 0 |
Alias Born | 10/28/2011 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, March 23, 2012 1:03:13 PM
Verisante is overdue and vastly undervalued at this point. Everyone, with few exceptions who has done significant research in this segment, is well aware. LOOK AT THE MARKET SEGMENT. When compared with the competition, having a 25x larger potential market for these devices, detecting not only melanoma but also the other 96% of skin cancers, consuming a fraction of the time 1 second vs. 2 minute scan time, and costing a fraction of the per-use-price for MD end-users $50 scan vs. $10/per disposable tip; Verisante brings only one word to mind.
SUPREMECY only becomes more well established with each news release. further, with the current securities lawsuit faced by the nearest competitor in this sector, having two, not 1 but count 'em 2-securities attorneys at the helm for Verisante is no laughing matter unless, of course, you take stock in VRS-canada/VRSEF-usa/V3T-germany.
LOVING IT,
Walt
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM